CONTEXT THERAPEUTICS INC (CNTX) Stock News
NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD
CNTX Latest News, Press Relases and Analysis
Unusual volume stocks in Friday's session
Let's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
These stocks that are showing activity before the opening bell on Thursday.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025...
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage...
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage...
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash...
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company...
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA,...
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into...
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x...
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Context Therapeutics to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Mentions: BCAB
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and...
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. ...
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents...
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager...